JP2025523369A5 - - Google Patents

Info

Publication number
JP2025523369A5
JP2025523369A5 JP2024570461A JP2024570461A JP2025523369A5 JP 2025523369 A5 JP2025523369 A5 JP 2025523369A5 JP 2024570461 A JP2024570461 A JP 2024570461A JP 2024570461 A JP2024570461 A JP 2024570461A JP 2025523369 A5 JP2025523369 A5 JP 2025523369A5
Authority
JP
Japan
Prior art keywords
product according
pharmaceutical product
index
domain variant
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024570461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025523369A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/067697 external-priority patent/WO2023235754A1/en
Publication of JP2025523369A publication Critical patent/JP2025523369A/ja
Publication of JP2025523369A5 publication Critical patent/JP2025523369A5/ja
Pending legal-status Critical Current

Links

JP2024570461A 2022-06-01 2023-05-31 尿路上皮癌腫を治療するための併用療法 Pending JP2025523369A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263347939P 2022-06-01 2022-06-01
US63/347,939 2022-06-01
PCT/US2023/067697 WO2023235754A1 (en) 2022-06-01 2023-05-31 Combination therapies for treating urothelial carcinoma

Publications (2)

Publication Number Publication Date
JP2025523369A JP2025523369A (ja) 2025-07-23
JP2025523369A5 true JP2025523369A5 (cg-RX-API-DMAC10.html) 2026-05-07

Family

ID=87036781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024570461A Pending JP2025523369A (ja) 2022-06-01 2023-05-31 尿路上皮癌腫を治療するための併用療法

Country Status (10)

Country Link
US (1) US20240010701A1 (cg-RX-API-DMAC10.html)
EP (1) EP4532548A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025523369A (cg-RX-API-DMAC10.html)
KR (1) KR20250022059A (cg-RX-API-DMAC10.html)
CN (1) CN119497722A (cg-RX-API-DMAC10.html)
AU (1) AU2023281712A1 (cg-RX-API-DMAC10.html)
CA (1) CA3253030A1 (cg-RX-API-DMAC10.html)
IL (1) IL316971A (cg-RX-API-DMAC10.html)
MX (1) MX2024014744A (cg-RX-API-DMAC10.html)
WO (1) WO2023235754A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021108693A1 (en) 2019-11-27 2021-06-03 ALX Oncology Inc. Combination therapies for treating cancer
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2874306T3 (es) 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
ME03550B (me) 2012-12-17 2020-07-20 Trillium Therapeutics Inc Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama
WO2016023040A1 (en) 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
CN106146670B (zh) 2015-04-24 2019-01-15 宜明昂科生物医药技术(上海)有限公司 一种新的重组双功能融合蛋白及其制备和应用
DK3298043T3 (da) 2015-05-18 2021-02-15 Ab Initio Biotherapeutics Inc SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
RU2740672C2 (ru) 2015-08-07 2021-01-19 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
DK4186927T3 (da) 2015-10-21 2025-06-10 Ose Immunotherapeutics Fremgangsmåder og sammensætninger til at ændre makrofagers polarisering til pro-inflammatoriske celler til behandling af kræft
WO2017177333A1 (en) 2016-04-15 2017-10-19 Trillium Therapeutics Inc. Macrophage stimulation in cd47 blockade therapy
EP3493845A4 (en) 2016-08-03 2020-04-15 The Board of Trustees of the Leland Stanford Junior University INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
WO2018081898A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
CA3042581A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
CN110325549B (zh) 2016-12-09 2024-03-08 艾利妥 抗SIRPα抗体及其使用方法
CN110300764A (zh) 2017-02-17 2019-10-01 Ose免疫疗法 抗SIRPg抗体的新用途
PT3443010T (pt) 2017-02-17 2024-10-21 Ose Immunotherapeutics Novos anticorpos anti-sirpa e suas aplicações terapêuticas
CA3057718A1 (en) 2017-03-28 2018-10-04 Trillium Therapeutics Inc. Cd47 blockade therapy
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー.ブイ. 抗sirpアルファ抗体
PT3625259T (pt) 2017-05-16 2024-07-04 Synthon Biopharmaceuticals Bv Anticorpos anti-sirpalfa
EP3658589B1 (en) 2017-07-26 2023-09-27 Forty Seven, Inc. Anti-sirp-alpha antibodies and related methods
WO2021108693A1 (en) * 2019-11-27 2021-06-03 ALX Oncology Inc. Combination therapies for treating cancer
JP2023542879A (ja) * 2020-09-17 2023-10-12 アジェンシス,インコーポレイテッド 191p4d12タンパク質に結合する抗体薬物複合体(adc)を用いたがんの治療方法

Similar Documents

Publication Publication Date Title
JP2023503943A5 (cg-RX-API-DMAC10.html)
JP2023528341A5 (cg-RX-API-DMAC10.html)
RU2483080C2 (ru) Антитела и иммуноконъюгаты и их применение
JP7729778B2 (ja) Fms様チロシンキナーゼ3(flt3)に対するキメラタンパク質およびキメラタンパク質複合体
JP2020520370A5 (cg-RX-API-DMAC10.html)
JP2021526512A5 (cg-RX-API-DMAC10.html)
JP2024520902A5 (cg-RX-API-DMAC10.html)
JP2018134080A (ja) イムノコンジュゲートを作製する抗体を修飾するための特定部位
JP2007500236A5 (cg-RX-API-DMAC10.html)
JP2015527318A5 (cg-RX-API-DMAC10.html)
JP2008530142A5 (cg-RX-API-DMAC10.html)
JP2019530434A5 (cg-RX-API-DMAC10.html)
JP2003531129A5 (cg-RX-API-DMAC10.html)
JP2004512262A5 (cg-RX-API-DMAC10.html)
WO2022155541A1 (en) Interferon prodrugs and methods of making and using the same
Govindan et al. New antibody conjugates in cancer therapy
IL274122B2 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
JP2022534212A5 (cg-RX-API-DMAC10.html)
JP2021501776A5 (cg-RX-API-DMAC10.html)
JP2020515577A5 (cg-RX-API-DMAC10.html)
JP2019524713A5 (cg-RX-API-DMAC10.html)
JP2024510142A5 (cg-RX-API-DMAC10.html)
WO2022268050A1 (zh) 一种药物组合及其用途
JP2023545432A5 (cg-RX-API-DMAC10.html)
JP2023536086A5 (cg-RX-API-DMAC10.html)